[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621253":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":27,"locations":33,"responsibleParty":48,"collaborators":11,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":54,"sex":60,"minAge":61,"maxAge":11,"enrollmentInfo":62,"targetDuration":11,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":75,"whyStopped":11,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Hospital Universitari de Bellvitge","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Retromesenteric reconstruction","EXPERIMENTAL",null,[13],"Procedure: Retromesenteric reconstruction",{"label":15,"type":16,"description":11,"interventionNames":17},"Transmesocolic reconstruction","ACTIVE_COMPARATOR",[18],"Procedure: Transmesocolic reconstruction",[20,24],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":11},"PROCEDURE","Perform a retromesenteric reconstruction after pancreaticoduodenectomy",[9],{"type":21,"name":15,"description":25,"armGroupLabels":26,"otherNames":11},"Perform the standard reconstruction procedure (transmesocolic) pancreaticoduodenectomy",[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},"Juli Busquets Barenys, Md, PhD","CONTACT","93 260 75 00","jbusquets@bellvitgehospital.cat",[34],{"facility":35,"status":11,"city":36,"state":37,"zip":38,"country":37,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Hopital Universitari de Bellvitge","L'Hospitalet de Llobregat","Spain","08907","ES",{"type":41,"coordinates":42},"Point",[43,44],2.10028,41.35967,{"lat":44,"lon":43},[47],{"name":29,"role":30,"phone":31,"phoneExt":11,"email":32},{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","BUSQUETS, JULI","Head of Pancreatic Surgery Unit","100621253","comparison-of-transmesocolic-versus-retromesenteric-reconstruction-in-cephalic-duodenopancreatectomy-fast-trial-100621253",false,"NCT07368218","Comparison of Transmesocolic Versus Retromesenteric Reconstruction in Cephalic Duodenopancreatectomy (FAST Trial)","Randomized Clinical Trial on Morbidity, Psychological Impact, and Changes in Biomarker Concentration During the Perioperative Period Comparing Transmesocolic Versus Retromesenteric Reconstruction in Cephalic Duodenopancreatectomy (FAST Trial)","FAST","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Candidates for cephalic duodenopancreatectomy due to pancreatic pathology\n* Ability to complete follow-up questionnaires\n\nExclusion Criteria:\n\n* Emergency surgery\n* Participation in another clinical trial\n* Pregnancy or lactation\n* Severe psychiatric disorder that prevents follow-up\n* Inability to understand the information and sign study consent","ALL","18 Years",{"count":63,"type":64},124,"ESTIMATED","INTERVENTIONAL",[67],"NA","Objective: To compare the incidence of delayed gastric emptying (ISGPS 2007 criteria) between patients undergoing retromesenteric versus transmesocolic reconstruction after pancreaticoduodenectomy. Secondary objectives include evaluating overall postoperative morbidity (Clavien-Dindo ≥ Grade I) at 90 days, postoperative pancreatic fistula according to ISGPF criteria, 30- and 90-day mortality, differences in operative time and blood loss, hospital stay duration, exploratory analysis of inflammatory biomarkers in serum and drainage fluid, psychological impact using SCL-90-R scale, and postoperative quality of life using EORTC QLQ-C30 scale.\n\nMethods: Randomized, controlled, single-center superiority clinical trial with 1:1 allocation. One hundred twenty-four patients candidates for duodenopancreatectomy due to pancreatic pathology will be randomized using balanced blocks to transmesocolic (control) or retromesenteric (study) reconstruction. Randomization will be revealed after completing the resection phase. Primary intention-to-treat analysis will estimate relative risk with 95% CI for dichotomous variables, Kaplan-Meier survival analysis with log-rank test, and linear mixed models for repeated measures in quality of life outcomes. Follow-up will be 90 days for the primary endpoint, extending to 12 months for secondary objectives.",[70],"Pancreatic Cancer",[72,73,74],"duodenopancreatectomy","Pancreatic cancer","Delayed Gastric emptying","NOT_YET_RECRUITING","2026-01-18",{"date":78,"type":79},"2026-01-26","ACTUAL",{"date":81,"type":64},"2026-01-31",{"date":83,"type":64},"2028-06",{"name":5,"class":6},1]